Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular carcinoma, cetuximab, Unresectable hepatocellular carcinoma, Metastatic hepatocellular carcinoma
Brief summary
The main purpose of this study is to begin to collect information and to try to learn whether or not cetuximab works in treating patients with unresectable or metastatic hepatocellular carcinoma.
Detailed description
The first step in this study is to examine the tumor biopsy (previously collected) and determine whether or not it is epidermal growth factor receptor (EGFR) positive or EGFR negative. Both EGFR positive and EGFR negative patients can participate in this study because at this time it is not known whether having a negative or positive receptor makes a difference in how the study drug works on the tumor. By knowing if the tumor is EGFR positive or negative, we will be able to see if there is a difference in the way the tumor responds to cetuximab. Patients will receive cetuximab intravenously once weekly for 6 weeks. Each 6-week period is one cycle of treatment. The first dose of cetuximab is larger than the following doses. For the first clinic visit the patient's blood pressure, temperature, breathing and heart rate will be taken before, during, at the end, and one-hour after the cetuximab has been administered. For each visit after that, blood pressure, temperature, breathing and heart rate will be taken before and after cetuximab has been administered. Before each administration of cetuximab, diphenhydramine will also be administered to decrease the chances of an allergic or hypersensitivity reaction. The following tests and procedures will be performed at weeks 1, 3 and 5 during each 6-week cycle of treatments as well as at the end of study treatment: physical exam, vital signs, medical history and blood work. At the end of each 6-week cycle a CT and/or MRI will be performed to measure the tumor size. Long-term follow-up will include physical exams and bloodwork every 6 months. Patients will remain on cetuximab as long as there is no disease progression or intolerable side effects.
Interventions
DRUGCetuximab
The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Sponsors
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Bristol-Myers Squibb
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Unresectable or metastatic hepatocellular carcinoma * Measurable tumor * Adequate hepatic function: total bilirubin \< 3.0mg/dl; AST \< 7 x upper limit of normal (ULN). * Adequate renal function: serum creatinine \< 2.0mg/dl * Adequate bone marrow function: absolute neutrophil count (ANC) \> 1,000/mm3; platelets \> 75,000/mm3. * 0-2 prior systemic chemotherapy regimens for hepatocellular carcinoma * 18 years of age and older * ECOG performance status of 0-2 * Life expectancy \> 12 weeks
Exclusion criteria
* Surgery, excluding prior diagnostic biopsy or venous access device placement, within 28 days of study entry * Uncontrolled serious medical or psychiatric illness * Irradiation or chemotherapy for disease within 28 days of study entry * Clinically apparent central nervous system metastases or carcinomatous meningitis * Received an investigational agent within 30 days * Cancer of the Liver Italian Program (CLIP) score \> 3 * Acute hepatitis * Active or uncontrolled infection * Significant history of cardiac disease * Prior cetuximab or other therapy which specifically and directly targets the EGFR pathway * Prior allergic reaction to chimerized or murine monoclonal antibody therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | 2 years |
| Overall Survival | 2 years |
| Objective Response Rate | 2 years |
Countries
United States
Outcome results
None listed